MS Active Source

positive living with MS

set site to small textset site to medium textset site to large text Home

Risk-Sharing Scheme

A study into the cost-effectiveness of disease-modifying treatments (DMTs) for MS (Avonex, Betaferon, Copaxone, Rebif) is currently ongoing in the UK (refT11). The study is organised by groups including the NHS, many other government departments, specialist nurse associations, neurologists and MS societies. People with RRMS or secondary progressive MS where relapses are dominant will be monitored and treated. All persons enrolled in the study must meet the criteria specified in the Association of British Neurologists guidelines, as discussed in other parts of the Treatment section.

The study is known as the risk-sharing scheme, but the risk is not to the MS patient. Instead, the risk is a financial one that will be shared by the pharmaceutical companies who make the DMTs. The risk is that the DMTs will not meet a cost-effectiveness target in the long term, and if this is the case it is agreed that the NHS will pay less for the drugs (refT12).


Nurse; Risk Sharing Scheme


More information can be found by going to www.mstrust.org.uk

Did you know?

How MS affects you will be very different to how it affects someone else.

Supported by

Biogen Idec

This website is intended for use in Great Britain and Northern Ireland.

Please click here for msactivesource.ie

Page last updated: 29 Jun 2009

This website is certified by Health On the Net Foundation. Click to verify. This site complies to the HONcode standard for trustworthy health information: verify here.